

## Special Issue

# State-of-the-Art Neurobiology and Neurologic Disease in Portugal

### Message from the Guest Editors

Portugal has a long reputation in the study of neurological and behavioral disorders. Going back to the pioneer work of Egas Moniz, the developer of cerebral angiography and one of the founders of modern psychosurgery, to the renowned neuroscientist António Damásio, who pursued the understanding of the boundaries between the mind and the brain, currently, there are several Portuguese physicians and researchers committed to improving the neurocognitive and neuropsychological profile of the individual in different contexts and phases of life. Importantly, the natural history of neurobiology and neurologic diseases in Portugal is marked by the occurrence of two rare hereditary disorders, the transthyretin familial amyloid polyneuropathy with endemic populations predominantly in the north of Portugal and Machado–Joseph disease with a high prevalence in the islands of Azores. This Special Issue is intended to honor the pioneering achievements made by Portuguese physicians in the neurology field and to present the scientific developments in epidemiology, diagnosis, and treatment of neurologic diseases in Portugal.

---

### Guest Editors

Dr. Cristina Carvalho

Dr. Sónia Catarina Correia

Dr. Susana Cardoso

---

### Deadline for manuscript submissions

closed (30 April 2023)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/93120](https://mdpi.com/si/93120)

*Biomedicines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).